| 產品名稱 |
SNU-5 |
| 商品貨號 |
B165741 |
| Organism |
Homo sapiens, human |
| Tissue |
stomach; derived from metastatic site: ascites |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
suspension, multicell aggregates |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
gastric carcinoma |
| Age |
33 years |
| Gender |
female |
| Ethnicity |
Asian |
| Storage Conditions |
liquid nitrogen vapor phase |
| Karyotype |
This is a hypotetraploid human cell line with the modal chromosome number of 87 and 88 occurring in a total of 36% of cells. Cells having higher ploidies were found at 9.6%. Eighteen or more marker chromosomes were found in most cells, including paired der(1)t(1;21) (p36.3;q11.2); der(1)t(1;?) (p32;?); 7q+'s; del(6) (q23); 12q+; and i(17q); triple der(2)t(2;?13) (p25.3;q14.3); and other single markers. There are two kinds of 7q+'s: der(7)t(7;?) (q22.3;?) and der (7)t(7;?) (q32;?). Multiple copies of DMs were also found in most cells. Normal N1 was absent. N5, N7, N10, N19 and N20 had four copies in most cells. At least one normal X chromosome was detected, but the normal Y was absent. |
| Derivation |
SNU-5 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The patient had previously received chemotherapy including 5-fluorouracil, doxorubicin and mitomycin-C. Derived from metastatic site, ascites |
| Clinical Data |
33 years Asian female SNU-5 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The patient had previously received chemotherapy including 5-fluorouracil, doxorubicin and mitomycin-C. The cells express the surface glycoproteins carcinoembryonic antigen (CEA) and TAG-72. The cells are L-dopa decarboxylase (DDC) positive. |
| Antigen Expression |
Blood Type O; Rh + The cells express the surface glycoproteins carcinoembryonic antigen (CEA) and TAG 72. |
| Receptor Expression |
acetylcholine, muscarinic, expressed vasoactive intestinal peptide (VIP), expressed vasoactive intestinal peptide (VIP); acetylcholine, muscarinic |
| Oncogene |
myc +; erb B2 + |
| Effects |
Yes, the cells have a reported colony forming efficiency of 27% in semisolid medium. |
| Comments |
SNU-5 cells were positive for VIP receptors but lacked gastrin receptors. The cells express the surface glycoproteins carcinoembryonic antigen (CEA) and TAG-72. The cells are L-dopa decarboxylase (DDC) positive. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
|
| Subculturing |
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.These cells tend to grow in multi-cell aggregates that may lose viability when the clusters are broken or dispersed. Therefore cell counts and viabilities assays should not be performed.
Medium Renewal: Every 2 to 3 days |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
| STR Profile |
Amelogenin: X CSF1PO: 12 D13S317: 8,9 D16S539: 13 D5S818: 10 D7S820: 8,12 THO1: 9 TPOX: 11 vWA: 15,16 |
| Population Doubling Time |
34 hrs |
| Name of Depositor |
J Park |
| Deposited As |
Homo sapiens |
| Year of Origin |
1987 |
| References |
Park JG, et al. Characteristics of cell lines established from human gastric carcinoma. Cancer Res. 50: 2773-2780, 1990. PubMed: 2158397
NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
|
